KEY HIGHLIGHTS Primary endpoint relating to synovial fluid biomarkers achieved and positive top-line results reported for the PARA OA 008 phase 2 clinical.
KEY HIGHLIGHTS Paradigm has been invited to present results from the mucopolysaccharidosis (MPS) program, with an oral presentation at the XVII International.
Key Highlights Paradigm as an NFL Alumni Health corporate member has entered into a research partnership to inform NFL Alumni members about osteoarthritis (OA).
Key Highlights Paradigm as an NFL Alumni Health corporate member has entered into a research partnership to inform NFL Alumni members about osteoarthritis (OA).
/PRNewswire/ Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a clinical-stage biopharmaceutical company focused on repurposing.